

=> d his; d bib,ab

(FILE 'HOME' ENTERED AT 14:29:03 ON 04 AUG 2004)

FILE 'CA' ENTERED AT 14:29:23 ON 04 AUG 2004  
L1 2166 S "W/O/W" OR WATER-IN-OIL-IN-WATER  
L2 281 S INTERFACIAL POLYMERIZ?  
L3 0 S L1 AND L2  
L4 57105 S ENCAPSUL? OR MICROENCAPSUL? OR MICROCAPSUL?  
L5 365 S L1 AND L4  
L6 0 S INTERFACIAL POLYMERIS?  
L7 391 S INTERFACIAL POLYMER?  
L8 4383 S INTERFACIAL(3A) POLYMER?  
L9 (2) S L5 AND L8

L9 ANSWER 1 OF 2 CA COPYRIGHT 2004 ACS on STN  
AN 122:64219 CA  
TI Polylactide microparticles prepared by double emulsion/evaporation technique. I. Effect of primary emulsion stability  
AU Nihant, Nicole; Schugens, Chantal; Grandfils, Christian; Jerome, Robert; Teyssie, Philippe  
CS Center for Education and Research on Macromolecules (CERM), University of Liege, Liege, 4000, Belg.  
SO Pharmaceutical Research (1994), 11(10), 1479-84  
CODEN: PHREEB; ISSN: 0724-8741  
PB Plenum  
DT Journal  
LA English  
AB The process of **microencapsulation** of proteins by double emulsion/evaporation in a matrix of polylactide (PLA) can be divided into three successive steps: first, an aqueous solution of the active compound is emulsified into an organic solution of the hydrophobic coating polymer; second, this primary water-in-oil emulsion (w/o) is dispersed in water with formation of a double **water-oil-water** emulsion (w/o/w); third, the organic solvent is removed with formation of solid microparticles. This paper focuses on the effect of primary emulsion stability on the morphology and properties of polylactide microparticles loaded with bovine serum albumin (BSA) used as model drug. Depending on the stability of the primary emulsion, the internal structure of microparticles can be changed from a multivesicular to a matrix-like structure. Similarly, the average porosity can be controlled in a range from a few tenths of a micron to approx. 20 to 30  $\mu$ . This morphological control could find potential applications not only for the controlled drug delivery but also for the production of microporous particles intended for some specific applications, such as cell culture supports and chromatographic matrixes. Although, the interplay of several processing parameters (polymer precipitation rate, **polymer** copolymer with **interfacial** compds. such as protein or surfactant, stirring rate) may not be disregarded, this study also indicated that a high loading of a hydrophilic drug can only be expected from a stable primary emulsion. When the stability of the primary emulsion is such as to prevent formation of macropores ( $>10 \mu\text{m}$ ), the total pore volume is close to that of the originally dispersed aqueous drug solution

=> d bib,ab 2

L9 ANSWER 2 OF 2 CA COPYRIGHT 2004 ACS on STN  
AN 113:138427 CA  
TI The effect of acacia, gelatin and polyvinylpyrrolidone on chloroquine transport from multiple **w/o/w** emulsions  
AU Omotosho, J. A.  
CS Fac. Pharm., Obafemi Awolowo Univ., Ile-Ife, Nigeria  
SO International Journal of Pharmaceutics (1990), 62(1), 81-4  
CODEN: IJPHDE; ISSN: 0378-5173  
DT Journal  
LA English  
AB The formation of multiple **water-oil-water** (**w/o/w**) emulsions with improved stability due to the formation of interfacial complex films between acacia, gelatin, polyvinylpyrrolidone and sorbitan monooleate is described. The long-term stability of the emulsions as assessed by microscopy showed no significant changes in **w/o/w** emulsions prepared with acacia in the internal phase, indicating good stability in these systems. Multiple emulsions containing chloroquine phosphate in the internal phase and which had been stored for 2 wk surprisingly showed a reduced rate of release of chloroquine phosphate as compared with freshly prepared emulsions, suggesting that the release of chloroquine phosphate from these systems occurs by the process of diffusion as opposed to the phys. breakdown of emulsions. It is suggested that the i.m. administration of chloroquine in the form of **w/o/w** emulsions could reduce the frequency of administration, improve patient compliance and increase the therapeutic efficacy of chloroquine. The drug can be formulated as a single dose system in which the starting dose is incorporated into the external phase while the maintenance dose is **encapsulated** in the internal phase of the emulsion.

=> => s tdi toluène diisocyanate  
16165 TDI  
149756 TOLUENE  
42930 DIISOCYANATE  
L10 16 TDI TOLUENÉ DIISOCYANATE  
(TDI (W) TOLUENE (W) DIISOCYANATE)

=> s tdi or toluene diisocyanate  
16165 TDI  
149756 TOLUENE  
42930 DIISOCYANATE  
3684 TOLUENE DIISOCYANATE  
(TOLUENE(W)DIISOCYANATE)  
L11 18577 TDI OR TOLUENE DIISOCYANATE

=> s 15 and 111  
L12 (1) L5 AND L11

=> d bib,ab

L12 ANSWER 1 OF 1 CA COPYRIGHT 2004 ACS on STN  
AN 135:304986 CA  
TI **Water-in-oil-water** emulsion  
IN Rodham, David Kirkham; Ramsay, Guy; Brown, David Joseph; Tadros, Tharwat Pouad  
PA Syngenta Ltd., UK  
SO PCT Int. Appl., 32 pp.  
CODEN: PIXXD2  
DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001078888	A1	20011025	WO 2001-GB1613	20010409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1276554	A1	20030122	EP 2001-969030	20010409
	EP 1276554	B1	20040616		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004501740	T2	20040122	JP 2001-576180	20010409
	US 2002025986	A1	20020228	US 2001-836468	20010418
PRAI	GB 2000-9735	A	20000419		
	WO 2001-GB1613	W	20010409		

AB The emulsion comprises a continuous aqueous phase having dispersed therein oil phase droplets wherein each oil phase droplet contains an inner dispersion of aqueous phase droplets, a water-soluble or water-dispersible active material being dissolved or dispersed in the inner dispersion of aqueous phase droplets and at least one of the inner dispersion and the oil phase droplets being **encapsulated** within a polymer wall material. Thus, an aqueous solution of paraquat dichloride 54.02 parts was mixed with 38.3 parts xylene in the presence of Atlox 4912 (polyhydroxystearic acid PEG ester) 7.64 parts to give a water-in-oil emulsion, to which (5.7 parts) was added 0.61 parts of **TDI** and 0.44 parts of diethylenetriamine to give a **water**-in-oil-in-water emulsion.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>